What the doctor ordered? : the economics of drug reimportation by Aaron Steelman
I
f there is a concept that enjoys
almost universal support among
economists, free trade is it. Accord-
ing to a survey published in the American
Economic Review, 95 percent of U.S.
economists agreed with the proposition
that “tariffs and import quotas reduce
general economic welfare.” So the case
of drug reimportation should be clear-
cut, right? Not exactly.
American drug companies routinely
sell their goods abroad at prices lower
than those found in the United States.
For instance, many American consumers
could probably order their prescriptions
more cheaply from a pharmacy in
Toronto than one in Baltimore. Why
not allow those drugs to be sent back
to  the United States for sale at Cana-
dian prices, a practice that is currently
prohibited by law?
That’s a good question, says Rep.
Gil Gutknecht (R-Minn.). He says that
people who regularly take prescription
drugs should be able to buy their med-
icines from pharmacies abroad — and
has introduced a bill that would legal-
ize the practice. Gutknecht, who rep-
resents a largely agricultural district,
argues that if free trade in farm prod-
ucts is a good thing, then free trade in
prescription drugs should be as well.
“The more I studied the differences
between what Americans pay for pre-
scription drugs and what the rest of the
industrialized world pays for those
same drugs, the more I came to the
conclusion that if markets work with
pork bellies, they will work with
Prilosec,” he has said.
This analogy may seem apt, but
many economists argue that the case is
more complicated. Drugs are unlike
other goods because they are often
extremely expensive to develop. For
instance, industry estimates put the
average cost of developing a new drug
at $800 million. That cost has to be
recouped in some way. Canadian law,
though, puts strict limits on drug prices,
setting the maximum price just above
the marginal cost of production. That
may seem fair. But it does not take into
account the high research expenses that
drug companies face, which drive up the
average cost of pharmaceuticals. If drug
companies relied on the Canadian
market alone, they probably could not
turn a profit on many of their goods.
So why do they enter the market at all?
Here it might be useful to draw an
analogy with the airline industry. The
cost of putting a plane in the air is
roughly the same whether that plane is
empty or full. So once the airline has
sold enough tickets to make the flight
profitable, it has a strong incentive to
fill the rest of the seats, even if that
means charging less for the 50th ticket
sold than the first.
The case of prescription drugs is
similar. In order to make a profit, the
pharmaceutical company needs a rela-
tively large market that is willing to
purchase its drugs at relatively high
prices. In most cases, that market is
the United States. This allows con-
sumers in other countries with
pharmaceutical price controls, such as
Canada, to effectively act as free riders.
Having already recouped their research
expenses, pharmaceutical companies are
willing to sell their goods abroad at
lower prices, because the cost of making
and distributing, say, the one millionth
Prilosec pill is quite small.
So what would happen under a
regime of drug reimportation? It’s hard
to say for sure, of course. But econo-
mists have offered some informed
speculation. American drug companies
might sharply cut their shipments of
drugs abroad, knowing that those
goods would wind up back in the
United States. Or they might try to
renegotiate the prices they can charge
in foreign markets, raising the average
global price, and thus reducing the
potential economic damage they face
from reimportation. Neither scenario
would do much to help American con-
sumers and could potentially harm
foreign consumers a good deal.
A better solution, instead, may be
to encourage other industrialized coun-
tries to relax their price control regimes.
The vast majority of pharmaceuticals are
developed in the United States. Part of
that is because American companies
employ researchers — many of whom
are foreign born — with the knowledge
required to produce groundbreaking
drugs. But part of it is also due to the
structure of the U.S. health-care system.
American companies are rewarded in
the marketplace for developing drugs
that make our lives better and longer.
If other countries were to liberalize their
systems, they, too, might become home
to  innovative pharmaceutical firms —
companies that could compete with
American incumbents and drive down
prices for everyone. RF
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